Why the study?
Dalteparin has traditionally been the first-line treatment for cancer-associated VTE, but direct oral anticoagulants like rivaroxaban may offer comparable efficacy with oral administration convenience.
Does rivaroxaban reduce recurrent VTE and major bleeding events compared to dalteparin in adults with cancer-associated venous thromboembolism?
Does rivaroxaban reduce recurrent VTE and major bleeding events compared to dalteparin in adults with cancer-associated venous thromboembolism?
This meta-analysis demonstrates that oral rivaroxaban is a viable alternative to injectable dalteparin for cancer-associated VTE, significantly reducing DVT recurrence while maintaining comparable major bleeding risk.
Answers are grounded in this paper and cite their sources.
Rivaroxaban offers comparable safety to dalteparin in cancer-associated VTE; extends RCT evidence supporting oral DOAC preference.
Background and aims: Traditionally, low molecular weight heparin, such as dalteparin, has been the first-line treatment for cancer-associated venous thromboembolism (VTE). However, recent studies suggest that rivaroxaban, a direct oral anticoagulant, may offer comparable efficacy with the convenience of oral administration. This systematic review and meta-analysis aim to evaluate and compare the efficacy and safety of rivaroxaban versus dalteparin in managing cancer-associated VTE, focusing on recurrence rates, bleeding events, and patient adherence. Methods: This review follows the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols guidelines, systematically retrieving data from PubMed and Cochrane databases using structured search terms related to cancer, VTE, and anticoagulation. Data on recurrent VTE, major bleeding, and patient outcomes were extracted. Statistical analyses were performed using a random-effects model to account for heterogeneity. Results: Nine studies were analyzed, encompassing a range of study designs across multiple countries. The findings show no significant difference in major bleeding risk between rivaroxaban and dalteparin (risk ratio: 0.91, P = 0.69), nor in bleeding-related mortality (odds ratio [OR]: 4.00, P = 0.36). Rivaroxaban was associated with a significant reduction in deep vein thrombosis (DVT) recurrence (OR: 0.75, P = 0.04) and a marginally nonsignificant reduction in pulmonary embolism recurrence (OR: 0.73, P = 0.05). Nonsignificant bleeding events were slightly higher with rivaroxaban but did not reach statistical significance. Conclusion: Rivaroxaban presents a viable alternative to dalteparin for treating cancer-associated VTE, showing comparable safety regarding major bleeding and potential efficacy in reducing DVT recurrence. This study supports the potential for more standardized guidelines that include rivaroxaban as a feasible option in cancer-associated VTE management.
No takes yet. Share an insight, caveat, or question.
Shrestha et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: